Clinical trial / 2019
Soy milk consumption alongside a calorie-deficit diet improved insulin, insulin resistance, and blood pressure in patients with NAFLD.
Sixty-six patients with NAFLD were randomly assigned to a 500-calorie deficit diet either with or without 240 ml/day of soy milk for 8 weeks. Compared to the control group, the soy milk group showed significantly greater reductions in serum insulin (-3.44 ± 5.02 vs. -1.09 ± 3.77 μIU/ml, P = 0.04), HOMA-IR (-0.45 ± 0.64 vs -0.14 ± 0.47, P = 0.03), systolic BP (-3.81 ± 4.15 vs -1.48 ± 2.93 mmHg, P = 0.01), and diastolic BP (-2.39 ± 2.80 vs. -0.94 ± 2.76 mmHg, P = 0.04), plus a significant increase in QUICKI (0.02 ± 0.032 vs. 0.008 ± 0.018, P = 0.04). Changes in fasting blood sugar, HOMA-β%, fibrinogen, and malondialdehyde did not differ significantly between groups.
- Study type
- Randomized, parallel, controlled trial
- Who was studied
- 66 patients diagnosed with non-alcoholic fatty liver disease (NAFLD)
- What was measured
- Fasting blood sugar, insulin, HOMA-IR, HOMA-β%, QUICKI, MDA, fibrinogen, and blood pressure
THE PAPER
Effect of soy milk consumption on glycemic status, blood pressure, fibrinogen and malondialdehyde in patients with non-alcoholic fatty liver disease: a randomized controlled trial.
Maleki Z, Jazayeri S, Eslami O, Shidfar F, Hosseini AF, Agah S, Norouzi H. Complement Ther Med, 2019.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.